ChemoCentryx

$56.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.67 (-1.17%) As of 7:20 PM UTC today

Why Robinhood?

You can buy or sell ChemoCentryx and other stocks, options, and ETFs commission-free!

About CCXI

ChemoCentryx, Inc. Common Stock, also called ChemoCentryx, is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA. The listed name for CCXI is ChemoCentryx, Inc. Common Stock.

CEO

Thomas J. Schall

Employees

Headquarters

Mountain View, California

Founded

1996

Market Cap

4.28B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

584.19K

High Today

$59.23

Low Today

$56.30

Open Price

$57.38

Volume

225.62K

52 Week High

$70.29

52 Week Low

$30.72

CCXI News

BenzingaMar 1

ChemoCentryx: Q4 Earnings Insights

Shares of ChemoCentryx (NASDAQ:CCXI) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 65.

Analyst Ratings

88%

of 8 ratings

Buy

88%

Hold

13%

Sell

CCXI Earnings

-$0.43

-$0.19

$0.05

$0.29

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$0.33 per share

Actual

-$0.43 per share

Replay Earnings Call